Potassium and sleep measures
What a small study of potassium chloride and different sleep measures showed.
Key points
- In a one-week crossover study of healthy young men, automated assessment of recordings showed less wake time after sleep onset with potassium chloride than placebo; manual assessment found no significant difference. This preliminary signal does not reliably support expecting less wake time at night. [1] See the evidence 1
- In the study, the diary sleep interval was shorter and depended on treatment order, while total time by automated assessment did not convincingly increase. This comparison does not support expecting a confirmed increase in sleep duration. [1] See the evidence 1 2
Practical guide
Check the conclusions and whether they apply to your situation.
Automated and manual sensor assessment, diary and total sleep time yield different results.
Key points
Why these conclusions
The sleep study
Healthy young men with normal blood potassium received microencapsulated potassium chloride 96 mEq daily or placebo on a diet containing about 40 mEq potassium daily. Periods lasted one week each; sensor recordings were available for six of nine participants. [1]
Automated assessment showed higher sleep efficiency and less wake time after sleep onset; manual assessment found statistically nonsignificant differences. Certainty is very low. [1]
The diary sleep interval was shorter and depended on intervention order; total sleep time by automated assessment did not convincingly increase. [1]
In the US, the National Academies of Sciences, Engineering, and Medicine (NASEM) have not established an upper limit for total potassium intake in healthy people with normal kidney function. Large doses of supplements or salt substitutes can cause a dangerous rise in blood potassium, sometimes without obvious symptoms. [2]
In chronic kidney disease, heart or adrenal failure and other conditions with impaired potassium excretion, ordinary references for healthy people cannot be considered an individually safe dose. [2]
Automated actigraphy showed higher sleep efficiency than placebo; the difference was statistically nonsignificant by manual assessment.
| Parameter | Data |
|---|---|
| Result | Automated actigraphy showed higher sleep efficiency than placebo; the difference was statistically nonsignificant by manual assessment. 93.8±3.2% versus 89.2±5.1%, p<0.05. Manual assessment was statistically nonsignificant. |
| Participants | 9 healthy young men with normal serum potassium; actigraphy in 6 |
| Form | Microencapsulated potassium chloride (Micro-K); diet with about 40 mEq potassium daily from food |
| Dose | 96 mEq potassium daily as chloride |
| Dose basis | 96 mEq potassium daily as chloride |
| Comparator | Placebo on the same diet |
| Duration | 1 week per period, crossover |
| Confidence | 1/4: Study methods: Loss of three recordings, dependence on method or order. Consistency: No grounds for a separate downgrade. Applicability to the specified group: Specific restricted diet and short protocol. Precision: 9 participants, actigraphy in 6. Possible publication bias: No specific data for a separate downgrade. |
| Evidence base | 1 crossover trial (9 participants; 6 sensor recordings; four outcomes from one study) |
| Sources | [1] |
Automated actigraphy showed less wake time after sleep onset than placebo; the difference was statistically nonsignificant by manual assessment.
| Parameter | Data |
|---|---|
| Result | Automated actigraphy showed less wake time after sleep onset than placebo; the difference was statistically nonsignificant by manual assessment. 25.8±15.0 versus 47.4±20.9 minutes, p<0.05. Manual assessment was statistically nonsignificant. |
| Participants | 9 healthy young men with normal serum potassium; actigraphy in 6 |
| Form | Microencapsulated potassium chloride (Micro-K); diet with about 40 mEq potassium daily from food |
| Dose | 96 mEq potassium daily as chloride |
| Dose basis | 96 mEq potassium daily as chloride |
| Comparator | Placebo on the same diet |
| Duration | 1 week per period, crossover |
| Confidence | 1/4: Study methods: Loss of three recordings, dependence on method or order. Consistency: No grounds for a separate downgrade. Applicability to the specified group: Specific restricted diet and short protocol. Precision: 9 participants, actigraphy in 6. Possible publication bias: No specific data for a separate downgrade. |
| Evidence base | 1 crossover trial (9 participants; 6 sensor recordings; four outcomes from one study) |
| Sources | [1] |
The diary sleep interval was shorter than placebo; the result depended on intervention order.
| Parameter | Data |
|---|---|
| Result | The diary sleep interval was shorter than placebo; the result depended on intervention order. 416±52 versus 439±56 minutes, p<0.01 in the abstract; interaction with order p=0.04. |
| Participants | 9 healthy young men with normal serum potassium; actigraphy in 6 |
| Form | Microencapsulated potassium chloride (Micro-K); diet with about 40 mEq potassium daily from food |
| Dose | 96 mEq potassium daily as chloride |
| Dose basis | 96 mEq potassium daily as chloride |
| Comparator | Placebo on the same diet |
| Duration | 1 week per period, crossover |
| Confidence | 1/4: Study methods: Loss of three recordings, dependence on method or order. Consistency: No grounds for a separate downgrade. Applicability to the specified group: Specific restricted diet and short protocol. Precision: 9 participants, actigraphy in 6. Possible publication bias: No specific data for a separate downgrade. |
| Evidence base | 1 crossover trial (9 participants; 6 sensor recordings; four outcomes from one study) |
| Sources | [1] |
Total sleep time by automated actigraphy did not convincingly increase.
| Parameter | Data |
|---|---|
| Result | Total sleep time by automated actigraphy did not convincingly increase. 386±58 versus 394±80 minutes, statistically nonsignificant. |
| Participants | 9 healthy young men with normal serum potassium; actigraphy in 6 |
| Form | Microencapsulated potassium chloride (Micro-K); diet with about 40 mEq potassium daily from food |
| Dose | 96 mEq potassium daily as chloride |
| Dose basis | 96 mEq potassium daily as chloride |
| Comparator | Placebo on the same diet |
| Duration | 1 week per period, crossover |
| Confidence | 1/4: Study methods: Loss of three recordings, dependence on method or order. Consistency: No grounds for a separate downgrade. Applicability to the specified group: Specific restricted diet and short protocol. Precision: 9 participants, actigraphy in 6. Possible publication bias: No specific data for a separate downgrade. |
| Evidence base | 1 crossover trial (9 participants; 6 sensor recordings; four outcomes from one study) |
| Sources | [1] |
In the US, the National Academies of Sciences, Engineering, and Medicine (NASEM) have not established an upper limit for total potassium intake in healthy people with normal kidney function. Large doses of supplements or salt substitutes can cause a dangerous rise in blood potassium, sometimes without obvious symptoms.
In the US, the National Academies of Sciences, Engineering, and Medicine (NASEM) have not established an upper limit for total potassium intake in healthy people with normal kidney function. Large doses of supplements or salt substitutes can cause a dangerous rise in blood potassium, sometimes without obvious symptoms. [2]
In chronic kidney disease, heart or adrenal failure and other conditions with impaired potassium excretion, ordinary references for healthy people cannot be considered an individually safe dose.
In chronic kidney disease, heart or adrenal failure and other conditions with impaired potassium excretion, ordinary references for healthy people cannot be considered an individually safe dose. [2]
Sources
- Potassium affects actigraph-identified sleep. https://gwern.net/doc/zeo/1991-drennan.pdf
- Potassium - Health Professional Fact Sheet. https://ods.od.nih.gov/factsheets/Potassium-HealthProfessional/
Methodology: Subpages evidence-led supplement pipeline v1